Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Brown, J. R., Eichhorst, B., Hillmen, P., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Šimkovič, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2022). Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study. Blood, 140(Supplement 2), LBA-6-LBA-6. https://doi.org/10.1182/blood-2022-171538
Authors:
Jennifer R. Brown
Barbara Eichhorst
Peter Hillmen
Nicole Lamanna
Susan O’Brien
Constantine S. Tam
Lugui Qiu
Maciej Kaźmierczak
Wojciech Jurczak
Keshu Zhou
Martin Šimkovič
Jiří Mayer
Amanda Gillespie-Twardy
Alessandra Ferrajoli
Peter Ganly
Robert Weinkove
Sebastian Grosicki
Andrzej Mital
Tadeusz Robak
Anders Österborg
Habte Yimer
Tommi Salmi
Megan Wang
Lina Fu
Jessica Li
Kenneth K. Wu
Aileen Cohen
Mazyar Shadman
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2022-171538
DOI:
10.1182/blood-2022-171538
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: